
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00.
Shares of Bicycle Therapeutics are trading down 5.7% over the last 24 hours, at $23.48 per share.